免疫调节治疗对神经炎症中κ 轻链作为生物标志物的影响。
The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation.
机构信息
Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Department of Clinical Immunology & Rheumatology, Hanover Medical School, 30625 Hanover, Germany.
出版信息
Cells. 2020 Mar 31;9(4):842. doi: 10.3390/cells9040842.
BACKGROUND
Kappa free light chains (KFLC) are a promising new biomarker to detect neuroinflammation. Still, the impact of pre-analytical effects on KFLC concentrations was not investigated.
METHODS
KFLC concentrations were measured in serum and cerebrospinal fluid (CSF) of patients with a newly diagnosed multiple sclerosis (MS) or clinically isolated syndrome (CIS) before (n = 42) or after therapy with high-dose methylprednisolone (n = 65). In prospective experiments, KFLC concentrations were analyzed in the same patients in serum before and after treatment with high-dose methylprednisolone (n = 16), plasma exchange (n = 12), immunoadsorption (n = 10), or intravenous immunoglobulins (n = 10). In addition, the influence of storage time, sample method, and contamination of CSF with blood were investigated.
RESULTS
Patients diagnosed with MS/CIS and treated with methylprednisolone showed significantly lower KFLC concentrations in serum as untreated patients. Repeated longitudinal investigations revealed that serum KFLC concentrations continuously decreased after each application of methylprednisolone. In contrast, other immune therapies and further pre-analytical conditions did not influence KFLC concentrations.
CONCLUSION
Our results show prominent effects of steroids on KFLC concentrations. In contrast, various other pre-analytical conditions did not influence KFLC concentrations, indicating the stability of this biomarker.
背景
κ 游离轻链（KFLC）是一种很有前途的新型生物标志物，可用于检测神经炎症。然而，目前尚未研究分析前因素对 KFLC 浓度的影响。
方法
本研究纳入了新诊断为多发性硬化症（MS）或临床孤立综合征（CIS）的患者 42 例，采集其治疗前血清和脑脊液（CSF）标本，同时纳入治疗后接受大剂量甲基泼尼松龙（n = 65）治疗的患者 65 例。前瞻性实验纳入了 16 例接受大剂量甲基泼尼松龙、12 例接受血浆置换、10 例接受免疫吸附或 10 例接受静脉注射免疫球蛋白治疗的患者，在治疗前后采集其血清标本，分析 KFLC 浓度。此外，还研究了储存时间、样本采集方法和 CSF 血污染对 KFLC 浓度的影响。
结果
与未接受治疗的患者相比，新诊断为 MS/CIS 且接受甲基泼尼松龙治疗的患者血清 KFLC 浓度显著降低。重复的纵向研究表明，每次应用甲基泼尼松龙后，血清 KFLC 浓度持续下降。相比之下，其他免疫治疗和进一步的分析前条件并未影响 KFLC 浓度。
结论
本研究结果表明类固醇对 KFLC 浓度有显著影响。相比之下，各种其他分析前条件并未影响 KFLC 浓度，提示该生物标志物具有稳定性。
Zotero 插件